Evidence map›Paper›PMID 37503019›Full record

ArticleResearch square2023

Leveraging Generative AI to Prioritize Drug Repurposing Candidates: Validating Identified Candidates for Alzheimer's Disease in Real-World Clinical Datasets.

Wei-Qi Wei, Chao Yan, Monika Grabowska, Alyson Dickson, Bingshan Li, Zhexing Wen, Dan Roden, C Stein, Peter Embí, Josh Peterson and 2 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Wei-Qi WeiVanderbilt University.
Chao YanVanderbilt University Medical Center.ORCID 0000-0002-6719-1388
Monika GrabowskaVanderbilt University Medical Center.ORCID 0000-0003-0708-676X
Alyson DicksonVanderbilt University Medical Center.
Bingshan LiVanderbilt University Medical Center.
Zhexing WenEmory University School of Medicine.
Dan RodenVanderbilt University Medical Center.
C SteinVanderbilt University Medical Center.
Peter EmbíVanderbilt University Medical Center.
Josh PetersonVanderbilt University Medical Center.
QiPing FengVanderbilt University Medical Center.
Bradley MalinVanderbilt University Medical Center.
Vanderbilt University Medical Center · USEmory University · USVanderbilt University · US

Funding

Understanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RODEN, DAN M · 2015 to 2019
$13.0M
Drug repositioning for Alzheimer's disease via genetics, electronic health records, and human iPSC modelsR01AG069900 · NIA · VANDERBILT UNIVERSITY · PI LI, BINGSHAN, WEI, WEI-QI · 2021 to 2025
$4.0M
Genetics and Triglycerides: opportunities for new approaches to identify therapiesR01HL163854 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI FENG, QIPING · 2022 to 2025
$3.1M
PheMAP: Measured, Automated Profile to Facilitate High Throughput PhenotypingR01GM139891 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WEI, WEI-QI · 2021 to 2024
$1.7M
Pharmacogenetics to improve drug therapyR35GM131770 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STEIN, CHARLES M. · 2019 to 2023
$1.7M
Computational drug repurposing for Alzheimer's diseaseF30AG080885 · NIA · VANDERBILT UNIVERSITY · PI Monika Eliana Grabowska · 2023 to 2026
$177k
NIA NIH HHS F30 AG080885NIA NIH HHS R01 AG069900NIGMS NIH HHS P50 GM115305NIGMS NIH HHS R01 GM139891NIGMS NIH HHS R35 GM131770
6 · The paper itself

Abstract

Drug repurposing represents an attractive alternative to the costly and time-consuming process of new drug development, particularly for serious, widespread conditions with limited effective treatments, such as Alzheimer's disease (AD). Emerging generative artificial intelligence (GAI) technologies like ChatGPT offer the promise of expediting the review and summary of scientific knowledge. To examine the feasibility of using GAI for identifying drug repurposing candidates, we iteratively tasked ChatGPT with proposing the twenty most promising drugs for repurposing in AD, and tested the top ten for risk of incident AD in exposed and unexposed individuals over age 65 in two large clinical datasets: 1) Vanderbilt University Medical Center and 2) the

Identifiers

PMID37503019
PMCPMC10371084
OpenAlexW4384296642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.